$OSCR earnings report

Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook. AlphAI read Oscar Health's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readOSCR · Third Quarter 2026 · ended September 30, 2026

Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook

✓Strong quarter

Third-quarter revenue, underwriting ratios, operating income, net income, and Adjusted EBITDA all improved materially from the prior-year quarter, while the company raised each of its full-year operating outlook ranges.

Revenue
$5.14B
EPS · GAAP
$ 0.49
Updated Full Year 2026 Outlook outlook
$19.0 billion to $19.3 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30GAAP$5.14B––
Premium revenue, three months ended September 30GAAP$5.04B––
Investment income, three months ended September 30GAAP$91.02M––
Other revenues, three months ended September 30GAAP$6.29M––
Medical expenses, three months ended September 30GAAP$4.23B––
Medical loss ratio, three months ended September 30other84.0 %––
Selling, general, and administrative expense, three months ended September 30GAAP$721.9M––
SG&A expense ratio, three months ended September 30other14.0%––
Depreciation and amortization, three months ended September 30GAAP$6.54M––
Total operating expenses, three months ended September 30GAAP$4.96B––
Earnings (loss) from operations, three months ended September 30GAAP$178.0M––
Interest expense, three months ended September 30GAAP$4.73M––
Other expenses (income), three months ended September 30GAAP−$2.09M––
Earnings (loss) before income taxes, three months ended September 30GAAP$175.4M––
Income tax expense (benefit), three months ended September 30GAAP$8.08M––
Net income (loss), three months ended September 30GAAP$167.3M––
Net income (loss) attributable to Oscar Health, Inc., three months ended September 30GAAP$167.3M––
Basic earnings (loss) per share, three months ended September 30GAAP$ 0.54––
Diluted earnings (loss) per share, three months ended September 30GAAP$ 0.49––
Adjusted EBITDA, three months ended September 30non-GAAP$206.9M––
Total revenue, nine months ended September 30GAAP$14.67B––
Medical loss ratio, nine months ended September 30other78.1 %––
SG&A expense ratio, nine months ended September 30other14.4%––
Earnings (loss) from operations, nine months ended September 30GAAP$1.27B––
Net income (loss) attributable to Oscar Health, Inc., nine months ended September 30GAAP$1.21B––
Diluted earnings (loss) per share, nine months ended September 30GAAP$ 3.59––
Adjusted EBITDA, nine months ended September 30non-GAAP$1.35B––
Individual and Small Group effectuated membership as of September 30other2,691,885––
Cigna+Oscar effectuated membership as of September 30other—––
Total effectuated members as of September 30other2,691,885––
Net cash provided by operating activities, nine months ended September 30GAAP$3.51B––
Net cash used in investing activities, nine months ended September 30GAAP−$1.85B––
Net cash provided by financing activities, nine months ended September 30GAAP$20.55M––
Increase in cash, cash equivalents and restricted cash equivalents, nine months ended September 30GAAP$1.69B––
Cash and cash equivalents as of September 30, 2026GAAP$4.47B––
Short-term investments as of September 30, 2026GAAP3,021,732––
Long-term investments as of September 30, 2026GAAP1,441,909––
Long-term debt as of September 30, 2026GAAP432,410––
Total assets as of September 30, 2026GAAP$10.01B––
Total liabilities as of September 30, 2026GAAP7,783,186––
Total stockholders' equity as of September 30, 2026GAAP2,225,794––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Updated Full Year 2026 Outlook outlook

  • Revenue$19.0 billion to $19.3 billion
  • NoteMedical loss ratio: 80.5% to 81.5%
  • NoteSG&A expense ratio: 15.1% to 15.6%
  • NoteEarnings from operations: $850 million to $950 million

What drove it

  • The increase in third-quarter total revenue was driven by rate increases and higher membership.
  • Revenue for the third quarter of 2026 included a $250 million benefit from updated risk adjustment estimates, driven by favorable development in the Company’s risk scores relative to the market and modestly favorable market morbidity relative to expectations.
  • The decrease in MLR was primarily driven by the Company’s disciplined pricing strategy.
  • The decrease in the SG&A expense ratio was primarily due to lower risk adjustment as a percentage of premium, greater fixed cost leverage, and disciplined expense management.
  • The increase in earnings from operations reflected strong operating performance driven primarily by improved underwriting performance.

Concerns

  • Third-quarter revenue included a $250 million benefit from updated risk adjustment estimates.
  • The Company had $42 million of favorable prior period development in the third quarter of 2026, compared to $84 million in the third quarter of 2025.
  • The filing identifies uncertainty around risk adjustment programs, medical-cost and market-morbidity estimates, ACA-related laws and regulations, the expiration of enhanced Advanced Premium Tax Credits, and capital reserve and surplus requirements.
  • Cigna+Oscar membership was — as of September 30, 2026, following the decision not to renew the Cigna+Oscar Small Group arrangement after December 31, 2024.

What to watch

  • Full-year 2026 execution against updated total revenue guidance of $19.0 billion to $19.3 billion.
  • Whether full-year MLR lands within the updated 80.5% to 81.5% range.
  • Whether the SG&A expense ratio remains within the updated 15.1% to 15.6% range as membership grows.
  • The sustainability of favorable risk adjustment estimates and prior-period development.
  • Progress toward the updated full-year earnings from operations range of $850 million to $950 million.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 4,466,858 as of September 30, 2026, compared with $ 2,774,151 as of December 31, 2025.
  • Short-term investments were 3,021,732 and long-term investments were 1,441,909 as of September 30, 2026.
  • Long-term debt was 432,410 as of September 30, 2026, compared with 430,095 as of December 31, 2025.
  • Net cash provided by operating activities was $ 3,510,737 for the nine months ended September 30, 2026, compared with $ 422,951 for the nine months ended September 30, 2025.
  • Net cash used in investing activities was $ (1,845,926) for the nine months ended September 30, 2026, compared with $ (192,354) for the nine months ended September 30, 2025.
  • Net cash provided by financing activities was $ 20,548 for the nine months ended September 30, 2026, compared with $ 391,040 for the nine months ended September 30, 2025.

Analysis

Oscar Health reported a substantially stronger third quarter than the prior-year period. Total revenue was approximately $5.1 billion compared to $3.0 billion, while earnings from operations were $178.0 million compared to a loss from operations of $129.3 million. Net income attributable to Oscar Health, Inc. was $167.3 million, or $0.49 of diluted earnings per share, compared to a net loss of $137.5 million, or $(0.53) of diluted loss per share. Adjusted EBITDA was $206.9 million compared to an adjusted EBITDA loss of $101.5 million.

Revenue expansion reflected rate increases and higher membership, with total effectuated members of 2,691,885 as of September 30, 2026, versus 2,116,904 a year earlier. The reported quarter also included a $250 million benefit from updated risk adjustment estimates. Management attributed that benefit to favorable development in its risk scores relative to the market and modestly favorable market morbidity relative to expectations.

Underwriting and expense ratios improved. MLR was 84.0%, compared with 88.5%, with the company citing disciplined pricing as the primary factor. The SG&A expense ratio was 14.0%, compared with 17.5%, reflecting lower risk adjustment as a percentage of premium, greater fixed-cost leverage, and disciplined expense management. Favorable prior-period development was $42 million in the quarter, compared with $84 million in the prior-year period, making risk adjustment and reserve development key determinants of reported profitability.

Nine-month operating cash flow was $3,510,737, compared with $422,951, and cash and cash equivalents were $4,466,858 as of September 30, 2026. Long-term debt was 432,410. The company raised its full-year 2026 outlook, moving total revenue to $19.0 billion to $19.3 billion, MLR to 80.5% to 81.5%, SG&A expense ratio to 15.1% to 15.6%, and earnings from operations to $850 million to $950 million. The higher outlook places continued pricing discipline, medical-cost management, risk adjustment outcomes, and expense leverage at the center of the remaining full-year execution.

Management, verbatim

Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time.

Mark Bertolini, CEO of Oscar Health

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Free cash flow was not reported.
  • No dividends, share repurchases, or other capital-return program was reported.
  • A quarterly operating cash flow figure was not reported.
  • A reported income tax rate was not provided.
  • Segment revenue was not reported.
  • Guidance for earnings per share, Adjusted EBITDA, cash flow, or capital returns was not provided.
  • Balance-sheet comparative figures are presented as of December 31, 2025, rather than a prior-year or prior-quarter period supported by the Metric schema.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readOSCR · second quarter 2026 · ended June 30, 2026

Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook

✓Strong quarter

Second-quarter revenue, underwriting metrics, operating earnings, net income, diluted earnings per share, and Adjusted EBITDA all improved versus the second quarter of 2025, while the Company raised its full-year outlook for medical loss ratio, SG&A expense ratio, and earnings from operations.

Revenue
$4.88B
EPS · GAAP
$1.10 of diluted earnings
Updated Full Year 2026 Outlook outlook
$18.7 billion to $19.0 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended June 30, 2026GAAP$4.88B––
Medical loss ratio, three months ended June 30, 2026other79.2%––
SG&A expense ratio, three months ended June 30, 2026other14.2%––
Earnings from operations, three months ended June 30, 2026GAAP$388.6M––
Net income attributable to Oscar Health, Inc., three months ended June 30, 2026GAAP$361.8M––
Diluted earnings per share, three months ended June 30, 2026GAAP$1.10 of diluted earnings per share––
Adjusted EBITDA, three months ended June 30, 2026non-GAAP$415.3M––
Total revenue, six months ended June 30, 2026GAAP$9.53B––
Medical loss ratio, six months ended June 30, 2026other75.0%––
SG&A expense ratio, six months ended June 30, 2026other14.7%––
Earnings from operations, six months ended June 30, 2026GAAP$1.09B––
Net income attributable to Oscar Health, Inc., six months ended June 30, 2026GAAP$1.04B––
Adjusted EBITDA, six months ended June 30, 2026non-GAAP$1.14B––
Individual and Small Group effectuated membership as of June 30, 2026other2,963,002––
Cigna+Oscar effectuated membership as of June 30, 2026other—––
Total effectuated members as of June 30, 2026other2,963,002––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Updated Full Year 2026 Outlook outlook

  • Revenue$18.7 billion to $19.0 billion
  • NoteMedical Loss Ratio: 81.5% to 82.5%
  • NoteSG&A Expense Ratio: 15.6% to 16.1%
  • NoteEarnings from Operations: $500 million to $700 million

What drove it

  • Total revenue growth was driven by higher membership and rate increases, partially offset by an increase in the net risk adjustment transfer accrual.
  • The medical loss ratio decrease was primarily driven by disciplined pricing strategy and $164 million of favorable prior period reserve development.
  • The SG&A expense ratio decrease was primarily due to disciplined expense management, greater fixed cost leverage, and the impact of lower risk adjustment as a percentage of premium.
  • The increase in earnings from operations reflected strong operating performance driven primarily by improved underwriting performance and favorable prior period development.

Concerns

  • Second-quarter total revenue growth was partially offset by an increase in the net risk adjustment transfer accrual.
  • The second quarter of 2025 medical loss ratio included the entire first half impact of 2025 risk adjustment true-up driven by higher average market morbidity.
  • The Company identified risks relating to changes in federal or state laws or regulations, including the expiration of enhanced Advanced Premium Tax Credits, implementation of new program integrity rules pursuant to the Notice of Benefit and Payment Parameters for policy year 2027, and potential funding of a cost-sharing reduction program.
  • The Company identified risks relating to accurately estimating incurred medical expenses or overall market morbidity, risk adjustment programs, capital reserve and surplus requirements, and quota share reinsurance.

What to watch

  • Medical loss ratio performance against the updated full-year range of 81.5% to 82.5%.
  • SG&A expense ratio performance against the updated full-year range of 15.6% to 16.1%.
  • Earnings from operations performance against the updated full-year range of $500 million to $700 million.
  • Membership growth, rate increases, net risk adjustment transfer accruals, and prior period reserve development.

Analysis

Oscar reported substantial second-quarter improvement across revenue, underwriting and profitability. Total revenue was $4,880,220 (in thousands), compared with $2,863,945 (in thousands) in the second quarter of 2025. The Company attributed the increase to higher membership and rate increases, partially offset by an increase in the net risk adjustment transfer accrual. Total effectuated members were 2,963,002 as of June 30, 2026, compared with 2,027,148 as of June 30, 2025.

Underwriting and expense ratios improved materially. The medical loss ratio was 79.2%, compared with 91.1%, with the Company citing disciplined pricing strategy and $164 million of favorable prior period reserve development. The prior-year quarter included the entire first half impact of the 2025 risk adjustment true-up driven by higher average market morbidity. The SG&A expense ratio was 14.2%, compared with 18.7%, reflecting disciplined expense management, greater fixed cost leverage, and lower risk adjustment as a percentage of premium.

The improved operating profile produced earnings from operations of $388,635 (in thousands), compared with a loss from operations of $(230,483) (in thousands). Net income attributable to Oscar Health, Inc. was $361,808 (in thousands), or $1.10 of diluted earnings per share, compared with a net loss attributable to Oscar Health, Inc. of $(228,361) (in thousands), or $(0.89) of diluted earnings per share. Adjusted EBITDA was $415,349 (in thousands), compared with an Adjusted EBITDA loss of $(199,404) (in thousands). For the six months ended June 30, 2026, earnings from operations were $1,092,720 (in thousands), net income attributable to Oscar Health, Inc. was $1,040,804 (in thousands), and Adjusted EBITDA was $1,142,421 (in thousands).

The updated full-year outlook retains total revenue of $18.7 billion to $19.0 billion while improving the medical loss ratio range to 81.5% to 82.5% from 82.4% to 83.4%, the SG&A expense ratio range to 15.6% to 16.1% from 15.8% to 16.3%, and earnings from operations to $500 million to $700 million from $250 million to $450 million. The guide places the key focus on whether pricing discipline, membership growth, expense leverage and reserve development can support the improved full-year operating targets amid risk adjustment and regulatory uncertainty.

Management, verbatim

Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance.

Mark Bertolini, CEO of Oscar Health

Our superior operating performance and execution against the fundamentals of our strategy are accelerating the individual market.

Mark Bertolini, CEO of Oscar Health

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported financial metrics
  • Printed year-over-year percentage changes for reported financial metrics
  • Gross margin
  • Gross-margin guidance
  • Operating expenses as a dollar amount
  • Operating-expenses guidance
  • Tax rate
  • Tax-rate guidance
  • Cash and cash equivalents
  • Debt
  • Operating cash flow
  • Free cash flow
  • Share repurchases
  • Dividends
  • Segment revenue disclosures
  • Prior-release outlook for comparison to actual results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about OSCR earnings dates

When is Oscar Health's next earnings date?
AlphAI has no date for OSCR yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.